DOCSLIB.ORG

Thesis Submitted for the Degree of Doctor of Philosophy By

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

A Study of the Primary Inactivating Enzymes of Thyroliberin in the Synaptosomal Membranes of Bovine Brain Thesis Submitted for the Degree of Doctor of Philosophy By Rhona O’Leary B.Sc. Under the Supervision of Dr. Brendan O’Connor School of Biological Sciences Dublin City University March 1994 I declare that all the work reported in this thesis was performed by Rhona O'Leary, unless otherwise stated. Rhona O’Leary This work is dedicated to my parents, Michael and Nannette, for their endless support, encouragement and love long may it continue. He Wishes For The Cloths Of Heaven Had I the heavens’ embroidered cloths, Enwrought with golden and silver light, The blue and the dim and the dark cloths Of night and light and the half-light, I would spread the cloths under your feet: But I, being poor, have only my dreams; I have spread my dreams under your feet; Tread softly because you tread on my dreams. c. W .B.Yeats Acknowledgements I would like to thank my supervisor, Dr. Brendan O’Connor, for all his help, encouragement, support and friendship over the past five years. His amazing ability to always be good- humoured, understanding and positive-thinking was so much appreciated. Thanks also to my ‘lab-mates’, Philip, Damian and S6 an for their help with just about everything. I especially would like to thank Dr. Gerry Doherty, BRI, for all his help - the world of biochemistry is losing an excellent scientist when he leaves to further his work for a better and greener world. Thanks must also go to Dr. Gearoid O'Cuinn, RTC Galway, for his words of wisdom and Laura’s radiolabelled thyroliberin! Thanks to Dr. Ken Carroll, RTC Tallaght, who was always there to offer technical assistance over a pint. A special thank you to the staff, technichans, postgrads and Barbara of the School of Biological Sciences, DCU, who helped, amused, abused and befriended me, whenever appropriate! The following acknowledgements are for those special people who really made my life in DCU so brilliant: to Seanin and Damo, who entertained, proof-read, drank pints and are fab! to Tess, Jess and Ger, for all those cups of coffee when I really needed them to Hugh and Andy - my two knights in shining armour - You will never realise how much it meant to me to Louise, whose laugh is so infectious to Ina, who fed, spoilt and pampered me - now it is your turn! to the McCabes, my home away from home to Ger, who was always there to listen and finally to all my family, for everything that you have given to me, no words of thanks can ever express how I feel - Thank you. Abstract Over the past twenty years, there has been an accumulation of evidence indicating that certain peptides that exert biological effects outside the CNS, may also possess neurotransmitter or neuromodulator functions in brain. Thyroliberin (Thyrotropin-Releasing Hormone) was the first of these such peptides displaying a dual role as a hormone and as a neurotransmitter. Its ubiquitous distribution in the hypothalamus and in the extra-hypothalamic regions, and its diverse pharmacological and physiological effects are all features of its dual functions. The study of brain peptidases that hydrolyse thyroliberin is of importance in securing an understanding of the possible mechanisms for termination of its neurotransmitter or neuromodulator actions and the possible enzymic biotransformation of the the original peptide to cleavage products that themselves may exhibit biological activity. The brain peptidases involved in the primary degradation of thyroliberin studied to date are three forms of pyroglutamate aminopeptidase (PAP), a cytosolic, particulate and serum form, and a cytosolic prolyl endopeptidase (PE) activity. This work studied the primary degradation of thyroliberin by the enzymes found in the particulate fraction of bovine brain. It began by investigating the methods available for the quantitation of the particulate PAP activity, and the development of two new assays for its detection, the first a coupled enzyme fluorimetric assay, and the second, a spontaneous cyclisation assay. Using these assays, PAP activity from the synaptosomal membranes of bovine brain was purified and characterised for the first time. This enzyme proved to have many of the characteristics of the previously studied particulate PAP activities, with some notable differences. The particulate PAP activity was shown to be 230kDa in size, had a narrow substrate specificity, cleaving only thyroliberin or very closely related peptides, and displayed a high affinity for thyroliberin. It was inhibited by thiol protease inhibitors, had a requirement for DTT and was unaffected by EDTA. By combining these features, the particulate PAP from bovine brain appears to be a ‘hybrid’ form of the cytosolic and the particulate PAP activities previously studied. Prolyl endopeptidase is widely distributed, has a broad substrate specificty and has been previously characterised in the cytosolic fractions of many species. It is involved in the primary degradation of thyroliberin, producing the bioactive peptide, acid thyroliberin. Prior to this study, PE had only been characterised as a cytosolic activity, and despite references to the possibility of there being a particulate activity, it was never identified. PE activity was located on the synaptosomal membranes of bovine brain, and following vigorous salt-washing, osmotic shock and solubilisation with detergents, has been identified conclusively as a membrane- associated activity. It was purified from the synaptosomal membranes, and characterised as having a broad substrate specificity and a high affinity for thyroliberin (in fact a higher affinity than the particulate PAP). It was inhibited by some of the thiol protease inhibitors and some of the metal chelators, suggesting that it may be a thimet protease. It also is inhibited by the specific prolyl endopeptidase inhibitor, Z-Pro-prolinal. List of Abbreviations ACE: Angiotensin Converting Enzyme ACTH: Adrenocorticotrophin AMP: Adenosine Monophosphate CCK: Cholecystokinin cDNA: Complementary DNA cGMP: 3’, 5’-Cyclic Guanosine Monophosphate CNS: Central Nervous System CoA: Coenzyme A CRS: Cold Restraint Stress CSF: CerebroSpinal Fluid Cydo(His-Pro): His-Pro Diketopiperazine DAP IV: Dipeptidyl Aminopeptidase IV DFP: Diisopropyl Fluorophosphate DMSO: Dimethylsulphoxide DTT: Dithiothreitol EDTA: Ethylenediaminetetra Acetic Acid GABA: Gamma Aminobutyric Acid GH: Growth Hormone Gly-ProMCA: Glycylproline-7-amino-4-methyl Coumarin Z-Gly-ProMCA: N-Benzyloxycarbonyl-glycylproline-7-amino-4-methyl Coumarin <Glu: Pyroglutamic Acid (5-pyrrolidone-2-carboxylic acid) <Glu-His: Pyroglutamyl Histidine <Glu-His-Pro: Acid Thyroliberin <Glu-His-ProNH2 : Thyroliberin <Glu-His-ProOH: Acid Thyroliberin <Glu-MCA: Pyroglutamate-7-amino-4-methyl Coumarin <Glu-(Me)His-ProNH 2 : Pyroglutamyl methyl-histidine proline 7-amino-4-methyl Coumarin (a Thyroliberin Analogue) GPCR: G-Protein Coupled Receptors <Glu-ProNH2 : Pyroglutamyl Proline Amide (a Thyroliberin Analogue) 5-HT: Seretonin Ki: Inhibitor Constant Km: Michaelis Menten Constant LDH: Lactate Dehydrogenase LHRH: Luteinising Hormone Releasing Hormone MCA: 7-Amino-4-Methyl Coumarin ME: Median Eminence mRNA: Messenger Ribonucleic Acid MSH: Melanocyte-Stimulating Hormone NA: Naphthyl Amide PAP: Pyroglutamate Aminopeptidase PCMB: p-Chloromercuribenzoate PDMK: Pyroglutamyl Diazomethyl Ketone PE: Prolyl Endopeptidase PIT: Pituitary PKC: Protein Kinase C PMSF: Phenylmethane Sulphonyl Fluoride PPCE: Post Proline Cleaving Enzyme PRL: Prolactin Ps4: Preprothyroliberin PTU: Propylthiouracil SM: Sulphamethoxazole T3 : Triiodothyronine T4 : Tetraiodothyronine (thyroxine) TEMED: N-| N-| N’.N’.-Tetramethyl Sulphonic Acid TPA:12-o-Tetra-Decanyl-Phorbal-13-Acetate TRH: Thyrotropin Releasing Hormone TSH: Thyrotropin VIP: Vasoactive Intestinal Peptide Table of Contents Section 1. Introduction 1. Thyrotropin Releasing Hormone 1 1.1. Physiological Actions of Thyroliberin at the Level of the Adenohypophysis 2 1.2. Distribution of Thyroliberin 4 1.3. Thyroliberin as a Possible Neuroregulator 7 1.3.1. Action of thyroliberin on neurons 8 1.3.2. Release and reuptake of thyroliberin at synaptic terminals 8 1.3.3. Behavioural effects of thyroliberin 8 1.4. Thyroliberin Receptors 9 1.4.1. Cloning and functional characterisation of the thyroliberin receptor 11 1 .4.2. Internalisation of the thyroliberin receptor follows binding 11 1.4.3. Localisation of thyroliberin receptor mRNA 12 1 .4.4. Regulation of thyroliberin receptors 13 1.5. Thyroliberin Biosynthesis 14 1 .5.1. Distribution of the thyroliberin prohormone 15 1.5.2. Processing of the thyroliberin prohormone 16 1.6. Degradation of Thyroliberin 18 1.6.1. Pyroglutamate aminopeptidase 22 1.6.1.1. Inhibitors of the soluble PAP 23 1.6.2. The particulate PAP 24 1 .6 .2 .1 . The distribution of PAP II activity 26 1.6.3. Serum PAP 27 1 .6.4. PAP regulation 28 1.6.4.1. PAP regulation by thyroid hormones 28 1 .6.4.2. Significance of regulation studies in establishing the biochemical role of PAP I, PAP II and the serum thyroliberinase 30 1 .6.4.3. Regulation of pyroglutamyl aminopeptidase by steroid hormones 31 1 .6.4.4. Possible mechanisms of PAP enzyme regulation 33 1 .6.5. Prolyl endopeptidase activity 34 1.6.5.1. Tissue distribution of prolyl endopeptidase 38 1 .6.5.2. Characterisation of prolyl endopeptidase 39 1.6.5.3. Substrate specificity of prolyl endopeptidase 39 1 .6.5.4. Prolyl endopeptidase inhibitors 42 1.6.5.5. Prolyl endopeptidase actions on neuropeptides 47 1 .6.5.6. Regulation of prolyl endopeptidase activity 49 1.7. Further Degradation of the Primary Metabolites of Thyroliberin 50 1.8. Biotransformations 51 1.9. Thyroliberin Analogues 57 1.10 Age Dependent Changes in Thyroliberin-Degrading Activity 59 Section 2. Materials and Methods 2.1. Materials 62 2.2. Determination of Enzyme Activities 64 2.2.1. Thyroliberin specific pyroglutamate aminopeptidase activity 64 2.2.2. Development of two new assays for particulate pyroglutamate aminopeptidase activities 65 2.2.2.1. A fluorimetric coupled enzyme assay for synaptosomal PAP 65 2.2.2.2. Spontaneous cyclisation assay for particulate pyroglutamate aminopeptidase activity 6 6 2.2.3.
Recommended publications
  • Expression of POMC, Detection of Precursor Proteases, and Evidence

    Expression of POMC, Detection of Precursor Proteases, and Evidence

    ORIGINAL ARTICLE See related commentary on page 1934 Human Mast Cells in the Neurohormonal Network: Expression of POMC, Detection of Precursor Proteases, and Evidence for IgE-Dependent Secretion of a-MSH Metin Artuc1, Markus Bo¨hm2, Andreas Gru¨tzkau1, Alina Smorodchenko1, Torsten Zuberbier1, Thomas Luger2 and Beate M. Henz1 Human mast cells have been shown to release histamine in response to the neuropeptide a-melanocyte- stimulating hormone (a-MSH), but it is unknown whether these cells express proopiomelanocortin (POMC) or POMC-derived peptides. We therefore examined highly purified human skin mast cells and a leukemic mast cell line-1 (HMC-1) for their ability to express POMC and members of the prohormone convertase (PC) family known to process POMC. Furthermore, we investigated whether these cells store and secrete a-MSH. Reverse transcriptase-PCR (RT-PCR) analysis revealed that both skin mast cells and HMC-1 cells express POMC mRNA and protein. Expression of the POMC gene at the RNA level in HMC-1 cells could be confirmed by Northern blotting. Transcripts for both PC1 and furin convertase were detectable in skin-derived mast cells and HMC-1 cells, as shown by RT-PCR. In contrast, PC2 transcripts were detected only in skin mast cells, whereas transcripts for paired basic amino acid converting enzyme 4 (PACE4) were present only in HMC-1 cells. Radio- immunoassays performed on cell lysates and cell culture supernatants from human skin-derived mast cells disclosed immunoreactive amounts of a-MSH in both fractions. Stimulation with an anti-IgE antibody significantly reduced intracellular a-MSH and increased extracellular levels, indicating IgE-mediated secretion of this neuropeptide.
  • Receptor-Bound Somatostatin and Epidermal Growth Factor Are Processed Differently in GH4C1 Rat Pituitary Cells David H

    Receptor-Bound Somatostatin and Epidermal Growth Factor Are Processed Differently in GH4C1 Rat Pituitary Cells David H

    Receptor-bound Somatostatin and Epidermal Growth Factor Are Processed Differently in GH4C1 Rat Pituitary Cells David H. Presky, and Agnes Schonbrunn Department of Pharmacology, Harvard Medical School, and Laboratory of Toxicology, Harvard School of Public Health, Boston, Massachusetts 02115 Abstract. GH4CI cells, a clonal strain of rat pituitary from cells during dissociation incubations at 37"C tumor cells, have high-affinity, functional receptors showed that >90% of prebound ~25I-EGF was released for the inhibitory hypothalamic peptide somatostatin as ~2sI-tyrosine, whereas prebound [125I-Tyrl]SRIF was (SRIF) and for epidermal growth factor (EGF). In this released as a mixture of intact peptide (55%) and 1251- study we have examined the events that follow the tyrosine (45%). Neither chloroquine (0.1 mM), am- initial binding of SRIF to its specific plasma mem- monium chloride (20 mM), nor leupeptin (0.1 mg/ml) brane receptors in GH4C1 cells and have compared increased the amount of [125I-Tyr~]SRIF bound to the processing of receptor-bound SRIF with that of cells at 37"C. Furthermore, chloroquine and leupeptin EGF. When cells were incubated with [125I-Tyr~]SRIF did not alter the rate of dissociation or degradation of at temperatures ranging from 4 to 37"C, >80% of the prebound [12SI-Tyrl]SRIF. In contrast, these inhibitors specifically bound peptide was removed by extraction increased the amount of cell-associated ~2SI-EGF dur- with 0.2 M acetic acid, 0.5 M NaC1, pH 2.5. In con- ing 37"C binding incubations and decreased the subse- trast, the subeellular distribution of receptor-bound quent rate of release of 12sI-tyrosine.
  • Diamandis Thesis

    Diamandis Thesis

    !"!#$ CHEMICAL GENETIC INTERROGATION OF NEURAL STEM CELLS: PHENOTYPE AND FUNCTION OF NEUROTRANSMITTER PATHWAYS IN NORMAL AND BRAIN TUMOUR INITIATING NEURAL PRECUSOR CELLS by Phedias Diamandis A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy. Department of Molecular Genetics University of Toronto © Copyright by Phedias Diamandis 2010 Phenotype and Function of Neurotransmitter Pathways in Normal and Brain Tumor Initiating Neural Precursor Cells Phedias Diamandis Doctor of Philosophy Department of Molecular Genetics University of Toronto 2010 &'(!)&*!% The identification of self-renewing and multipotent neural stem cells (NSCs) in the mammalian brain brings promise for the treatment of neurological diseases and has yielded new insight into brain cancer. The complete repertoire of signaling pathways that governs these cells however remains largely uncharacterized. This thesis describes how chemical genetic approaches can be used to probe and better define the operational circuitry of the NSC. I describe the development of a small molecule chemical genetic screen of NSCs that uncovered an unappreciated precursor role of a number of neurotransmitter pathways commonly thought to operate primarily in the mature central nervous system (CNS). Given the similarities between stem cells and cancer, I then translated this knowledge to demonstrate that these neurotransmitter regulatory effects are also conserved within cultures of cancer stem cells. I then provide experimental and epidemiologically support for this hypothesis and suggest that neurotransmitter signals may also regulate the expansion of precursor cells that drive tumor growth in the brain. Specifically, I first evaluate the effects of neurochemicals in mouse models of brain tumors. I then outline a retrospective meta-analysis of brain tumor incidence rates in psychiatric patients presumed to be chronically taking neuromodulators similar to those identified in the initial screen.
  • Metabolic Enzyme/Protease

    Metabolic Enzyme/Protease

    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com Metabolic Enzyme/Protease Metabolic pathways are enzyme-mediated biochemical reactions that lead to biosynthesis (anabolism) or breakdown (catabolism) of natural product small molecules within a cell or tissue. In each pathway, enzymes catalyze the conversion of substrates into structurally similar products. Metabolic processes typically transform small molecules, but also include macromolecular processes such as DNA repair and replication, and protein synthesis and degradation. Metabolism maintains the living state of the cells and the organism. Proteases are used throughout an organism for various metabolic processes. Proteases control a great variety of physiological processes that are critical for life, including the immune response, cell cycle, cell death, wound healing, food digestion, and protein and organelle recycling. On the basis of the type of the key amino acid in the active site of the protease and the mechanism of peptide bond cleavage, proteases can be classified into six groups: cysteine, serine, threonine, glutamic acid, aspartate proteases, as well as matrix metalloproteases. Proteases can not only activate proteins such as cytokines, or inactivate them such as numerous repair proteins during apoptosis, but also expose cryptic sites, such as occurs with β-secretase during amyloid precursor protein processing, shed various transmembrane proteins such as occurs with metalloproteases and cysteine proteases, or convert receptor agonists into antagonists and vice versa such as chemokine conversions carried out by metalloproteases, dipeptidyl peptidase IV and some cathepsins. In addition to the catalytic domains, a great number of proteases contain numerous additional domains or modules that substantially increase the complexity of their functions.
  • That Are Not at L O

    That Are Not at L O

    THAT ARE NOT ATLUS009944652B2 O TTO (12 ) United States Patent ( 10 ) Patent No. : US 9 ,944 ,652 B2 Saltiel et al. ( 45 ) Date of Patent: * Apr. 17, 2018 ( 54 ) DEUTERATED AMLEXANOX 5 , 223 ,409 A 6 / 1993 Ladner 5 , 225 ,212 A 7 / 1993 Martin 5 , 225 , 326 A 7 / 1993 Bresser (71 ) Applicant: THE REGENTS OF THE 5 , 270 , 184 A 12 / 1993 Walker UNIVERSITY OF MICHIGAN , Ann 5 , 283 , 174 A 2 / 1994 Arnold , Jr . Arbor , MI (US ) 5 , 362 ,737 A 11/ 1994 Vora et al . 5 , 399 , 491 A 3 / 1995 Kacian ( 72 ) Inventors : Alan R . Saltiel, Ann Arbor, MI (US ) ; 5 ,455 , 166 A 10 / 1995 Walker 5 ,480 , 784 A 1 / 1996 Kacian Hollis D . Showalter, Ann Arbor, MI 5 ,545 , 524 A 8 / 1996 Trent (US ) ; Scott Larsen , Ann Arbor, MI 5 ,641 , 673 A 6 / 1997 Haseloff (US ) 5 , 710 ,029 A 1 / 1998 Ryder 5 ,814 ,447 A 9 / 1998 Ishiguro (73 ) Assignee : THE REGENTS OF THE 5 ,824 ,518 A 10 / 1998 Kacian UNIVERSITY OF MICHIGAN , Ann 5 , 925 , 517 A 7 / 1999 Tyagi 5 , 928 , 862 A 7 / 1999 Morrison Arbor , MI (US ) 5 , 981 , 180 A 11 / 1999 Chandler 6 ,074 ,822 A 6 / 2000 Henry ( * ) Notice : Subject to any disclaimer, the term of this 6 , 121 ,489 A 9 / 2000 Dorner patent is extended or adjusted under 35 6 , 150 , 097 A 11/ 2000 Tyagi U . S . C . 154 (b ) by 0 days . 6 , 200 , 763 B1 3 /2001 Craig et al . 6 , 221, 335 B1 * 4 /2001 Foster CO7B 59 /002 This patent is subject to a terminal dis 424 / 1 .
  • A Peptide-Hormone-Inactivating Endopeptidase in Xenopus Laevis Skin Secretion

    A Peptide-Hormone-Inactivating Endopeptidase in Xenopus Laevis Skin Secretion

    Proc. Nati. Acad. Sci. USA Vol. 89, pp. 84-88, January 1992 Biochemistry A peptide-hormone-inactivating endopeptidase in Xenopus laevis skin secretion (metailoendopeptidase/neutral endopeptidase/thermolysin) KRISHNAMURTI DE MORAIS CARVALHO*, CARINE JOUDIOU, HAMADI BOUSSETTA, ANNE-MARIE LESENEY, AND PAUL COHEN Groupe de Neurobiochimie Cellulaire et Moldculaire de l'Universitd Pierre et Marie Curie, Unit6 de Recherche Associ6e 554 au Centre National de la Recherche Scientifique, % Boulevard Raspail, 75006 Paris, France Communicated by I. Robert Lehman, September 16, 1991 ABSTRACT An endopeptidase was isolated from Xenopus Indeed the Ser-Phe dipeptide, or a related motif such as laevis skin secretions. This enzyme, which has an apparent Phe-Phe, Ala-Phe, or His-Phe, is often present near the molecular mass of 100 kDa, performs a selective cleavage at the carboxyl terminus of substances from the bombesin and Xaa-Phe, Xaa-Leu, or Xaa-Ile bond (Xaa = Ser, Phe, Tyr, His, tachykinin families (1). Xaa-Phe, Xaa-Leu, or Xaa-Ile was or Gly) of a number of peptide hormones, including atrial also found frequently at a similar position in other peptide natriuretic factor, substance P, angiotensin H, bradykinin, hormone sequences of higher organisms, notably in atrial somatostatin, neuromedins B and C, and litorin. The peptidase natriuretic factor (ANF). exhibited optimal activity at pH 7.5 and aKm in the micromolar We have purified this enzyme 2029-fold and demonstrate range. No cleavage was produced in vasopressin, ocytocin, that it inactivates ANF by exclusive cleavage of the Ser25- minigastrin I, and [Leu5Jenkephalin, which include in their Phe26 bond and similarly inactivates a number of important sequence an Xaa-Phe, Xaa-Leu, or Xaa-Ile motif.
  • Lessons Learned

    Lessons Learned

    Prevention and Reversal of Chronic Disease Copyright © 2019 RN Kostoff PREVENTION AND REVERSAL OF CHRONIC DISEASE: LESSONS LEARNED By Ronald N. Kostoff, Ph.D., School of Public Policy, Georgia Institute of Technology 13500 Tallyrand Way, Gainesville, VA, 20155 [email protected] KEYWORDS Chronic disease prevention; chronic disease reversal; chronic kidney disease; Alzheimer’s Disease; peripheral neuropathy; peripheral arterial disease; contributing factors; treatments; biomarkers; literature-based discovery; text mining ABSTRACT For a decade, our research group has been developing protocols to prevent and reverse chronic diseases. The present monograph outlines the lessons we have learned from both conducting the studies and identifying common patterns in the results. The main product of our studies is a five-step treatment protocol to reverse any chronic disease, based on the following systemic medical principle: at the present time, removal of cause is a necessary, but not necessarily sufficient, condition for restorative treatment to be effective. Implementation of the five-step treatment protocol is as follows: FIVE-STEP TREATMENT PROTOCOL TO REVERSE ANY CHRONIC DISEASE Step 1: Obtain a detailed medical and habit/exposure history from the patient. Step 2: Administer written and clinical performance and behavioral tests to assess the severity of symptoms and performance measures. Step 3: Administer laboratory tests (blood, urine, imaging, etc) Step 4: Eliminate ongoing contributing factors to the chronic disease Step 5: Implement treatments for the chronic disease This individually-tailored chronic disease treatment protocol can be implemented with the data available in the biomedical literature now. It is general and applicable to any chronic disease that has an associated substantial research literature (with the possible exceptions of individuals with strong genetic predispositions to the disease in question or who have suffered irreversible damage from the disease).
  • US5270302.Pdf

    US5270302.Pdf

    |||||||||||||||||| USOO527O3O2A United States Patent (19) 11 Patent Number: 5,270,302 Shiosaki et al. 45) Date of Patent: Dec. 14, 1993 (54) DERIVATIVES OF TETRAPEPTIDESAS CCK Stewart et al., (Solid Phase Peptide Synthesis, 2nd Ed, AGONSTS 1984, Pierce Chemical Company, Rockford, Ill., pp. 27 75 Inventors: Kazumi Shiosaki; Alex M. Nadzan, and 28. both of Libertyville; Hana Kopecka, Martinez, et al., J. Med., Chen. 1985, 28:1874. Vernon Hills; Youe-Kong Shue, Yabe et al., Chen. Pharm. Bull., 1977, 25:2731. Vernon Hills; Mark W. Holladay, Kovacs et al., "Cholesystokinin Analogs Containing Vernon Hills; Chun W. Lin, Wood Non-Coded Amino Acids', Pept Synthesis, Structure Dale; Hugh N. Nellans, Mundelein, and Function, Proc. 9th Am. Pept. Symp., 1985, pp. all of Ill. 583-586, 73) Assignee: Abbott Laboratories, Abbott Park, Primary Examiner-Lester L. Lee II. Attorney, Agent, or Firm-Richard A. Elder; Steven R. 21 Appl. No.: 713,010 Crowley; Steven F. Weinstock (22 Filed: Jun. 17, 1991 57 ABSTRACT Selective and potent Type-A CCK receptor agonists of Related U.S. Application Data formula (I): 63 Continuation-in-part of Ser. No. 541,230, Jun. 20, 1990, abandoned, which is a continuation-in-part of Ser. No. X-Y-2-Q (I) 5,673, Dec. 18, 1989, which is a continuation-in-part of Ser. No. 287,955, Dec. 21, 1988, abandoned. or a pharmaceutically acceptable salt thereof, wherein, X is selected from 51) Int. Cl........................ A61K 37/02; CO7K 5/08; CO7K 5/10 4 5 4 S 52 U.S. C. ........................................ 514/18; 514/17; R.
  • Structural and Functional Studies of Synaptic Enzymes

    Structural and Functional Studies of Synaptic Enzymes

    University of Kentucky UKnowledge University of Kentucky Doctoral Dissertations Graduate School 2006 STRUCTURAL AND FUNCTIONAL STUDIES OF SYNAPTIC ENZYMES Eun Jeong Lim University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Lim, Eun Jeong, "STRUCTURAL AND FUNCTIONAL STUDIES OF SYNAPTIC ENZYMES" (2006). University of Kentucky Doctoral Dissertations. 259. https://uknowledge.uky.edu/gradschool_diss/259 This Dissertation is brought to you for free and open access by the Graduate School at UKnowledge. It has been accepted for inclusion in University of Kentucky Doctoral Dissertations by an authorized administrator of UKnowledge. For more information, please contact [email protected]. ABSTRACT OF DISSERTATION Eun Jeong Lim Department of Molecular and Cellular Biochemistry College of Medicine University of Kentucky 2006 STRUCTURAL AND FUNCTIONAL STUDIES OF SYNAPTIC ENZYMES ABSTRACT OF DISSERTATION A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of Molecular and Cellular Biochemistry and College of Medicine at the University of Kentucky By Eun Jeong Lim Lexington, Kentucky Director: Dr. David W. Rodgers Associate Professor of Molecular and Cellular Biochemistry Lexington, Kentucky 2006 Copyright © Eun Jeong Lim, 2006 ABSTRACT OF DISSERTATION STRUCTURAL AND FUNCTIONAL STUDIES OF SYNAPTIC ENZYMES Thimet oligopeptidase (TOP, EC 3.4.24.15) and neurolysin (EC 3.4.24.16) are zinc dependent metallopeptidases that metabolize small bioactive peptides. The two enzymes share 60 % sequence identity and their crystal structures demonstrate that they adopt nearly identical folds. They generally cleave at the same sites, but they recognize different positions on some peptides, including neurotensin, a 13-residue peptide involved in modulation of dopaminergic circuits, pain perception, and thermoregulation.
  • Acute Pancreatitis

    Acute Pancreatitis

    ACUTE PANCREATITIS Edited by Luis Rodrigo Acute Pancreatitis Edited by Luis Rodrigo Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2011 InTech All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. As for readers, this license allows users to download, copy and build upon published chapters even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Vedran Greblo Technical Editor Teodora Smiljanic Cover Designer InTech Design Team Image Copyright Sebastian Kaulitzki, 2011. Used under license from Shutterstock.com First published December, 2011 Printed in Croatia A free online edition of this book is available at www.intechopen.com Additional hard copies can be obtained from [email protected] Acute Pancreatitis, Edited by Luis Rodrigo p.
  • Steroidal and Non-Steroidal Third-Generation Aromatase Inhibitors Induce Pain-Like Symptoms Via TRPA1

    Steroidal and Non-Steroidal Third-Generation Aromatase Inhibitors Induce Pain-Like Symptoms Via TRPA1

    ARTICLE Received 18 Apr 2014 | Accepted 3 Nov 2014 | Published 8 Dec 2014 DOI: 10.1038/ncomms6736 OPEN Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1 Camilla Fusi1,*, Serena Materazzi1,*, Silvia Benemei1,*, Elisabetta Coppi1, Gabriela Trevisan2, Ilaria M. Marone1, Daiana Minocci1, Francesco De Logu1, Tiziano Tuccinardi3, Maria Rosaria Di Tommaso4, Tommaso Susini4, Gloriano Moneti1,5, Giuseppe Pieraccini1,5, Pierangelo Geppetti1 & Romina Nassini1 Use of aromatase inhibitors (AIs), exemestane, letrozole and anastrozole, for breast cancer therapy is associated with severe pain symptoms, the underlying mechanism of which is unknown. The electrophilic nature of AIs suggests that they may target the transient receptor potential ankyrin 1 (TRPA1) channel, a major pathway in pain transmission and neurogenic inflammation. AIs evoke TRPA1-mediated calcium response and current in rodent nociceptors and human cells expressing the recombinant channel. In mice, AIs produce acute nociception, which is exaggerated by pre-exposure to proalgesic stimuli, and, by releasing sensory neuropeptides, neurogenic inflammation in peripheral tissues. AIs also evoke mechanical allodynia and decreased grip strength, which do not undergo desensitization on prolonged AI administration. These effects are markedly attenuated by TRPA1 pharmacological blockade or in TRPA1-deficient mice. TRPA1 is a major mediator of the proinflammatory/proalgesic actions of AIs, thus suggesting TRPA1 antagonists for the treatment of pain symptoms associated with AI use. 1 Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence 50139, Italy. 2 Laboratory of Biological and Molecular Biology, Graduate Program in Health Sciences, University of the Extreme South of Santa Catarina (UNESC), Santa Catarina 88806-000, Brazil.
  • (12) United States Patent (10) Patent No.: US 8,871,738 B2 Shao Et Al

    (12) United States Patent (10) Patent No.: US 8,871,738 B2 Shao Et Al

    USOO8871 738B2 (12) United States Patent (10) Patent No.: US 8,871,738 B2 Shao et al. (45) Date of Patent: Oct. 28, 2014 (54) FUSED BICYCLIC OXAZOLIDINONE CETP 2009.0075979 A1 3/2009 Ali et al. INHIBITOR 2009/O137548 A1 5/2009 Ali et al. 2013/0331372 A1 12/2013 Lu et al. (71) Applicant: Merck Sharp & Dohme Corp., Rahway, NJ (US) FOREIGN PATENT DOCUMENTS WO O3O11824 A1 2, 2003 (72) Inventors: Pengcheng Patrick Shao, Fanwood, NJ WO 2005100298 A1 10, 2005 (US); Wanying Sun, Edison, NJ (US); WO 2010O39474 A1 4/2010 Revathi Reddy Katipally, Monmouth WO 2011028395 A1 3, 2011 Junction, NJ (US); Petr Vachal, Summit, WO 2013165854 A1 11 2013 NJ (US); Feng Ye, Scotch Plains, NJ OTHER PUBLICATIONS (US); Jian Liu, Edison, NJ (US); Deyou Sha, Yardley, PA (US) Borsini; et al., "Intramolecular Palladium-Catalyzed Aminocarboxylation of Olefins as a Direct Route to Bicyclic (73) Assignee: Merck Sharp & Dohme Corp., Oxazolidinones', Advanced Synthesis & Catalysts, vol. 353, pp. Rahway, NJ (US) 985-994, (2011). International Search Report mailed on Dec. 10, 2012 for PCT/ US2012/061842, 8 pages. (*) Notice: Subject to any disclaimer, the term of this Agami, et al., Chiral oxazolidinones from O-hydroxy Oxazolidines: a patent is extended or adjusted under 35 new access to 1,2-amino alcohols, Tetrahedron: Asymmetry, 1998, U.S.C. 154(b) by 0 days. 3955-3958, 9. Davidson, MH. Update on CETP inhibition, Journal of Clinical (21) Appl. No.: 13/660,010 Lipidology, 2010, 394-398, 4. Kim, et al., Ring Opening of Homochiral Bicyclic Oxazolidinones: Filed: Oct.